What an FDA Advisory Committee Meeting on GLP-1 Drugs Actually Decides
FDA advisory committee meetings generate significant news coverage, but their recommendations are advisory, not binding. Here's how the process actually works.
By the GLP Semaglutide editorial team · Last updated May 28, 2025
FDA advisory committees are panels of outside experts convened to review data and vote on recommendations for specific drug approvals, label changes, or safety questions. Committee votes are influential but not legally binding on the FDA's final decision.
Why meetings get so much coverage
Advisory committee meetings are public, involve extensive data presentations from both the FDA and the drug sponsor, and often surface safety or efficacy debates that wouldn't otherwise be visible before a final approval decision — which is why they draw heavy news coverage.
What to watch for
The FDA typically, but not always, follows an advisory committee's recommendation. Meeting materials, transcripts, and voting results are published on the FDA's website and are the most direct way to follow a specific GLP-1-related review.
Primary sources